Kornimate/medical-research-clean huggingface dataset:
a study of ly2875358 in participants with met positive, advanced gastric cancer

Conditions: Gastric Cancer

Summary: the main purpose of this study is to evaluate the effectiveness of ly2875358 in participants with met diagnostic positive (+), advanced gastric or gastroesophageal junction (gej) cancer.


Eligibility criteria:
inclusion criteria: * have a diagnosis of a histopathologically or cytologically confirmed local and/or advanced gastric or gastroesophageal junction (gej) adenocarcinoma which is unresectable * have received 2 regimens of prior chemotherapies for gastric or gej adenocarcinoma * have the presence of measurable disease as defined by the response evaluation criteria in solid tumors (recist 1.1) * have consent to provide a tissue sample for pre-screening * determined to be met diagnostic positive based upon testing of a tumor sample obtained at any time before enrollment * have discontinued all previous treatments for cancer, including chemotherapy and radiotherapy, for at least 3 weeks before enrollment and have recovered from the acute effects of therapy * have adequate organ function * male participants: must agree to use a reliable method of birth control and to not donate sperm during the study and for at least 4 months following last dose of study drug or country requirements, whichever is longer * female participants: are women of child-bearing potential who test negative for pregnancy ≤14 days before enrollment based on a serum pregnancy test and agree to use a reliable method of birth control during the study and for 4 months following the last dose of the study drug and must also not be breastfeeding * have a performance status of ≤1 on the eastern cooperative oncology group (ecog) scale * have an estimated life expectancy, in the judgment of the investigator, of at least 12 weeks exclusion criteria: * are currently enrolled in, or discontinued within the last 21 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * have previously completed or withdrawn from this study or any other study investigating ly2875358 * have an active fungal, bacterial, and/or known viral infection * have a history of new york heart association class ≥3, unstable angina, myocardial infarction (mi) in 6 months prior to study drug administration * have symptomatic central nervous system (cns) malignancy or metastasis * have previous or concurrent malignancies * have received a liver transplant, or have liver cirrhosis with a child-pugh stage of b or c * have corrected qt interval (qtc) of \>470 millisecond (msec) on screening electrocardiogram (ecg) * have received previous treatment with any hepatocyte growth factor (hgf)/met targeting therapeutics * have a history of radiation therapy involving more than 25% of the bone marrow. previous radiation therapy is allowed but should have been limited and must not have included whole pelvis radiation
evaluation of disinfecting solutions and protein remover with a silicone hydrogel lens

Conditions: Ametropia

Summary: the purpose of this study is to determine if reduced lens deposits and increased comfort can be achieved by using multipurpose disinfecting solutions (mpds) in a no-rub format but in conjunction with an intensive cleaner, rather than using mpds in a rub format.

the purpose of this study is to determine if reduced lens deposits and increased comfort can be achieved by using multipurpose disinfecting solutions (mpds) in a no-rub format but in conjunction with an intensive cleaner, rather than using mpds in a rub format by observing changes within the cornea and collecting subjective ratings.

Eligibility criteria:
inclusion criteria: * is at least 17 years of age and has full legal capacity to volunteer. * has read, understood and signed an information consent letter. * is willing and able to follow instructions and maintain the appointment schedule. * is correctable to a visual acuity of 6/9 or better (in each eye) with their habitual vision correction. * has clear corneas and no active ocular disease. * has had an ocular examination in the last two years. * is a current soft lens wearer, replacing their lenses every two weeks to one month. * has a distance contact lens prescription between +6.00d to -10.00 ds and can be successfully fit with the study lens. * has astigmatism less than or equal to -1.00 dc. exclusion criteria: * has any signs or symptoms of dry eye. * has any clinically significant blepharitis. * has undergone corneal refractive surgery. * is aphakic. * has any active ocular disease. * has any systemic disease affecting ocular health. * is using any systemic or topical medications that may affect ocular health. * has known sensitivity to the diagnostic pharmaceuticals to be used in the study. * is pregnant or lactating. * is participating in any other type of clinical or research study. * currently wears daily disposable lenses. * currently wears lenses on an extended wear basis.

Keywords: comfort wetability protein deposit lipid deposit
visuomotor control in parkinson disease

Conditions: Parkinson Disease

Summary: visuomotor processing is the ability to integrate visual information into motor plans and movement correction, which is highly required in daily activities such as writing and walking. as visual impairments have been reported in people with parkinson's disease (pd), it is likely that those impairments may affect visuomotor processing ability and subsequently impair motor performance. furthermore, people with pd and freezing of gait (fog) have exhibited poorer visual perception than those without fog, yet the differences of visuomotor control have not been well investigated. additionally, little did the studies apply neurophysiological assessment to investigate the associated neural mechanisms. this study aims to investigate behavioral and neurophysiological differences in visuomotor control among people with pd and fog (freezers), without fog (non-freezers), and age-matched healthy controls. sixty-three participants, 21 freezers, 21 non-freezers, and 21 age-matched healthy controls, will be enrolled in this study. behavioral assessments, including a manual control task and visual perception tests will be used to evaluate visuomotor and visual perceptual abilities. neurophysiological correlates, including corticomotor excitability and corticocortical connectivity between v1-m1 and ppc-m1, will be examined using transcranial magnetic stimulation. it is hypothesized that freezers will demonstrate the greatest visuomotor impairments and disrupted corticocortical connectivity compared to non-freezers and controls. by integrating behavioral and neurophysiological outcomes, this study seeks to unravel the mechanisms linking visual and motor impairments to fog, ultimately providing insights into targeted interventions to improve visuomotor processing and motor performance in pd.


Eligibility criteria:
inclusion criteria: * age above 18 * able to follow the researchers' instructions * normal or correct-to-normal vision to view a computer screen exclusion criteria: * neurological disorders other than pd * diagnosed psychological disorders or a tendency of anxiety and/or depression * a self-history of seizure or a family history of epilepsy * deep brain stimulation or pacemaker implanted * unstable cardiovascular diseases or other uncontrolled medical conditions * pregnant * surgical history, severe injury, or severe tremor of their upper extremities that can affect their movements in the past 6 months

Keywords: parkinson disease transcranial magnetic stimulation motor control
mifi flutter registry - ablation of atrial flutter with intellatip sensor technology

Conditions: Atrial Flutter

Summary: * prospective atrial flutter ablation registry investigating intellatip mifi xp 8 mm technology and mvg isthmus ablation approach * design: national, multi-centre, prospective observational registry documenting right atrial isthmus ablation * observational treatment: combination of mvg ablation strategy and the intellatip mifi xp 8 mm sensor technology * duration: patients will be followed for 6 months post-ablation

the mifi flutter registry is a non-interventional, multi-centre, prospective registry in consecutive patients with atrial flutter and indication for right atrial isthmus ablation. the registry is an observational study and patient's participation in this study has no impact on his/her indication for treatment, diagnostics or therapy. patients are supposed to be treated according to current guidelines and the site's internal directives. treatment pattern and treatment initiation, continuation or changes are solely at the discre-tion of the physician and the patient. there will be no attempt to influence the treatment patterns of any individual treating physician. all drug prescriptions will be in the usual standard of care. participation in the registry will in no way influence payment or reimbursement for any treatment received by subjects during the study. a minimum of 10 hospitals in germany treating atrial flutter and using the maximum voltage-guided (mvg) ablation technique are eligible for participation. the enrolment period is estimated to be 6 months. eligible are all patients with atrial flutter, who will visit consecutively a participating site of the mifi flutter registry. it is planned to enrol approximately 120 patients in total. the follow-ups of patients will be performed using a standardized patient interview (telephone call) at 6 months by institut für herzinfarktforschung (ihf). in case of relevant complications, the treating physician is asked to provide medical records for verification. if the patient is not accessible by phone, local registration offices will be contacted for further information.

Eligibility criteria:
inclusion criteria: * atrial flutter and clinical indication for atrial flutter (afl) ablation * 18+ years * written informed consent for participation in observational study (incl. telephone follow-ups) * not simultaneously participating in any randomized trial * at least one ecg-documented, symptomatic, typical atrial flut-ter episode \>30sec. * isthmus ablation conducted in association with other ablation procedures (e.g. for atrial fibrillation) is permitted exclusion criteria: * any prior afl ablation * acute reversible causes for atrial flutter (e.g. acute myocarditis) * tricuspid valve replacement * right atrial thrombus * present pregnancy or breastfeeding woman * drug or alcohol abuse

Keywords: ablation mifi technology maximum voltage-guided ablation
a randomized controlled trial of iv ketorolac to prevent post-ercp pancreatitis

Conditions: Pancreatitis

Summary: determine if iv ketorolac is an effective agent in the prevention of post-ercp pancreatitis. determine if iv ketorolac provides improved post-procedure analgesia. determine if systemic mediators of inflammation are reduced in patients receiving iv ketorolac following ercp.

acute pancreatitis is the most common major complication of both diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ercp), accounting for substantial morbidity and an annual expenditure of approximately 150 million annually.(1,2) non-steroidal anti-inflammatory agents (nsaids) have been shown to be effective in multiple prospective randomized controlled trial for the prevention of post-ercp pancreatitis.(3-6) nsaids are postulated to inhibit phospholipase a2 and prostaglandin synthesis, which plays an important role in the inflammatory cascade in acute pancreatitis. rectal suppository indomethacin (a potent cox-2 inhibitor) has been effective in preventing post-ercp pancreatitis in clinical trials and is now recommended for routine use for ercp by the european society of gastrointestinal endoscopy.(7) toradol® (ketorolac), an nsaid available in iv form, is a more potent cox-2 inhibitor and analgesic than indomethacin.(8,9) ketorolac is routinely used postoperatively following major surgery to assist in pain control particularly following orthopedic procedures. iv ketorolac has never been evaluated for the prevention of post-ercp pancreatitis.

Eligibility criteria:
inclusion criteria: * all patients presenting to sfgh for ercp * age 18-85 * do not meet exclusion criteria exclusion criteria: * acute pancreatitis at the time of ercp * use of nsaids in the previous week * peptic ulcer disease * severe renal dysfunction * pregnancy * lithium therapy * allergy to ketorolac
endothelial function in young hispanic adults at risk for type 2 diabetes

Conditions: Obesity; Insulin Resistance

Summary: diabetes is a major public health problem. hispanics/latinos are known to be at higher risk for type 2 diabetes. the function of the endothelium has played a key role in the understanding of vascular complications in people with diabetes. endothelial function and vascular reactivity are impaired not only in white adults with type 2 diabetes but also in those at risk for the disease by virtue of having impaired glucose tolerance or parental history of type 2 diabetes. whether this finding is applicable to hispanics is not known. the investigators plan to assess the endothelial function and vascular reactivity in young hispanic adults at risk of developing type 2 diabetes by virtue of being obese and belonging to a minority population.


Eligibility criteria:
inclusion criteria: * group 1: 1. age between 18-40 years; 2. hispanic (we will consider a subject being hispanic if both parents are reported as hispanics when asked the following question: "what ethnic group do you consider that you belong to?"); 3. history of type 2 diabetes in one or both parents; 4. bmi above 27; 5. not have participated in any exercise program for the 6 months prior to the beginning of the study. group 2: 1. age between 18-40 years; 2. hispanic (same criteria as above ); 3. no history of type 2 diabetes in any first degree relative; 4. bmi under 25; 5. not have participated in any exercise program for the 6 months prior to the beginning of the study. exclusion criteria: * diabetes, glucose intolerance, pregnancy, smoking, cardiovascular disease, uncontrolled hypertension, renal disease, proteinuria, cancer, infectious diseases, severe gi diseases, lung disease, electrolyte abnormalities, anemia, endocrine disorders, severe dyslipidemia, peripheral vascular disease, medications: beta-blockers, any diuretic, calcium channel blockers, ace inhibitors, angiotensin receptor blockers, niacin, glucocorticoids, any antineoplastic agent, antibiotics, psychoactive agents, bronchodilators or insulin.
a study to gather information about rivaroxaban in patients in sweden with cancer who also have thrombosis (oscar-se)

Conditions: Treatment of Venous Thromboembolism in Cancer Patients

Summary: this is an observational study in which patient data from the past on venous thromboembolism (vte) in patients with cancer is studied. vte is a condition in which a patient has problems due to the formation of blood clots in the veins. blood clots can reduce the flow of blood to vital organs such as the heart and lungs, which can lead to them becoming damaged. vte can also be "recurrent". this means that the blood clots have returned after treatment. people who have cancer have an increased risk of developing vte. three main types of anticoagulation treatments ("blood thinners") have been available for patients with cancer who also have vte * low molecular weight heparins (lmwhs) * vitamin k antagonists (vkas) * non-vitamin k antagonist oral anticoagulants (noacs) the treatment rivaroxaban belongs to the noacs. compared to other treatments available to patients who have cancer and vte, noacs may cause fewer medical problems and can be easier for patients to take correctly. in this study, the researchers will collect data about: * the type of vte treatments given and for how long the treatments are taken * the risk of blood clots returning in the veins after treatment, any events of major bleeding, and the number of deaths in patients with cancer who do not have a high risk of bleeding the researchers will compare this information in the patients * who received rivaroxaban to the patients who received lmwhs * who received noacs to the patients who received lmwhs. there will be no required visits with a study doctor or required tests in this study. the researchers will look at the health information from adult patients in sweden who were diagnosed with cancer between 2013 and 2019 and also have vte. the researchers will collect this information from swedish health registers including the cancer registry, national patient registry, prescribed drug registry, and cause of death registry.


Eligibility criteria:
inclusion criteria: * a resident in sweden of 18+ years of age * a swedish person identification number * a diagnosis of cancer ((icd10 = c00-c97) in the swedish cancer registry during 2013-2019 and a diagnosis of vte subsequent to the cancer diagnosis. exclusion criteria: * a diagnosis of atrial fibrillation, total hip or knee replacement or acute coronary syndrome (for evaluation of treatment patterns) before the date of vte diagnosis * a dispensed prescription for any oral anticoagulant (oac) before the date of vte diagnosis * a cancer diagnosis associated with high bleeding risk, including upper gastrointestinal cancer, malignant immunoproliferative diseases and leukemia
exercise intervention in adolescent and young adult cancer survivors

Conditions: Long-term Effects Secondary to Cancer Therapy in Adults; Pediatric Cancer

Summary: adolescent and young adult (aya) survivors of cancer face a future of persistent medical issues across a wide spectrum of diseases one study examining health data from this cohort (ages 15-29) reported significantly higher rates of smoking, obesity, cardiovascular disease, hypertension, asthma, and poorer mental health among the cancer survivors when compared to healthy controls. prescribed exercise has broad and far-reaching beneficial physiological effects that cut across multiple body systems and consistently improves emotional well-being, decreases fatigue and depression, and enhances quality of life. although a growing body of evidence consistently demonstrates the physiological and psychological benefits of exercise interventions in adults with cancer, there are no studies examining the effects of individualized, prescribed, supervised exercise in pediatric, adolescent and young adult cancer survivors.


Eligibility criteria:
inclusion criteria: 1. age ≥ 15 and ≤ 39 years, 2. history of cancer 3. at least three months off of cytotoxic chemotherapy (note: hormone therapy is permitted) exclusion criteria: 1. evidence of significant liver dysfunction, congestive heart failure, cardiovascular disease 2. history of cns tumor 3. down's syndrome 4. unable to perform aerobic and/or strength exercises with full range of motion (limb immobilization, limb amputation, or surgical complications. 5. neurological disorder 6. baseline exercise of 30 minutes per day three times a week already being performed.
assessment of thoracolumbar fascia length

Conditions: Fascia

Summary: the purpose of the study is to compare the elasticity of thoracolumbar fascia in patients with and without subacromial impingement syndrome. 30 patients diagnosed as subacromial impingement syndrome in physical medicine and rehabilitation department of baskent university will be recruited as group 1. 30 healthy volunteers will be recruited as group 2. visual analogue scale (vas) with the aim of assessing pain severity, tape measurement for posterior capsule shortness; body lateral flexion, rotation and extensor movements and lumbar extensor shortness will be observed for correlation with thoracalumbal fascia flexibility. lateral flexion, flexion, and extension movements will be measured using goniometry for trunk normal joint movements. the thoracolumbar fascia length test and modify schober test will be used for thoracolumbar fascia length.


Eligibility criteria:
inclusion criteria: * 30 patients with subacromial impingement syndrome and 30 volunteers * between ages of 20-40 years * both sexes exclusion criteria: * having lumbar surgery * having problem with lumbar region in last 6 months * having scoliosis * radiologically diagnosed kiphosis * mr diagnosed lumbar and thoracic herniation * positive sacroiliac tests * restricted pelvic motion * having scapular dyskinesia

Keywords: thoracolumbar fascia subacromial impingement syndrome
dysport® treatment of urinary incontinence in adults subjects with neurogenic detrusor overactivity (ndo) due to spinal cord injury or multiple sclerosis - study 1

Conditions: Urinary Incontinence; Overactive Bladder

Summary: the purpose of this study is to provide confirmatory evidence of the safety and efficacy of two dysport® (abobotulinumtoxina) doses (600 units \[u\] and 800 u), compared to placebo in reducing urinary incontinence (ui) in adult subjects treated for neurogenic detrusor overactivity (ndo) due to spinal cord injury (sci) or multiple sclerosis (ms).


Eligibility criteria:
key inclusion criteria: * urinary incontinence for at least 3 months prior to screening as a result of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. * subjects with spinal cord injury must have a stable neurological injury at t1 level or below which occurred at least 6 months prior to screening. * subjects with multiple sclerosis must be clinically stable in the investigator's opinion, with no exacerbation (relapse) of ms for at least 3 months prior to screening. * subjects must have had an inadequate response after at least 4 weeks of oral medications used in the treatment of ndo (e.g. anticholinergics, beta-3 agonists) and/or have intolerable side-effects. * routinely performing clean intermittent catheterization (cic) to ensure adequate bladder emptying. * an average of at least two episodes per day of urinary incontinence recorded on the screening bladder diary. key exclusion criteria: * any current condition (other than ndo) that may impact on bladder function. * previous or current, tumour or malignancy affecting the spinal column or spinal cord, or any other unstable cause of sci. * any condition that will prevent cystoscopic treatment administration or cic usage, e.g. urethral strictures. * current indwelling bladder catheter, or removal of indwelling bladder catheter less than 4 weeks prior to screening. * btx-a treatment within 9 months prior to screening for any urological condition (e.g. detrusor or urethral sphincter treatments). * any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within 4 weeks prior to screening. any implanted neuromodulation device must be switched off at least 4 weeks prior to screening.